Amnestic Mild Cognitive Disorder
7
3
5
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (7)
Pathways Relating Amnestic MCI to a Mild Traumatic Brain Injury History
Low Intensity Focused Ultrasound for Mild Cognitive Impairment and Mild Alzheimer's Disease
Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study
Behavioral Change Following Alzheimer's Disease (AD) Biomarker Disclosure
Neuro RX Gamma for Amnestic Mild Cognitive Impairment (aMCI)
Modified Ketogenic Diet in Amnestic Mild Cognitive Impairments
Cognitive Effects of Roflumilast in (a)MCI and Mild Dementia Patients